<DOC>
	<DOCNO>NCT01684410</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , dose escalation study assess safety tolerability 100 mg 200 mg inhale Alpha-1 HC administer day three week subject age 18 year older cystic fibrosis ( CF ) . The treatment duration study intend provide multi-dose safety information prior proceeding long duration exposure .</brief_summary>
	<brief_title>Safety Tolerability Trial Inhaled Alpha1-Proteinase Inhibitor ( Human ) , Hydrophobic Chromatography Process ( Alpha-1 HC ) Subjects With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Age 18 year old . Documentation CF diagnosis . Have prebronchodilator FEV1 ≥ 40 % predict Visit 1 Visit 2 preinvestigational product FEV1 ≥ 40 % predict within ± 15 % Visit 1 result . Deemed Investigator suitable candidate serial collection expectorate sputum . Had pulmonary exacerbation 4 week screen ( Visit 1 ) require initiation new antibiotic treatment Have pulmonary exacerbation screen period ( Visit 1 Visit 2 ) require initiation new antibiotic treatment FEV1 &lt; 0.59 liter screen visit Respiratory insufficiency continuous supplemental oxygen therapy , carbon dioxide retention Elevated aspartate transaminase ( AST ) alanine aminotransferase ( ALT ) ≥ 3 time upper limit normal age gender Smoking past 6 month Lung surgery past 2 year Positive culture Burkholderia cepacia mycobacterium past two year . Active allergic bronchopulmonary aspergillosis Pretreatment sputum collection Visit 1 Visit 2 ( Randomization ) characterize problem inadequate sputum volume quality . Known selective Immunoglobulin A ( IgA ) deficiency know antibody IgA ( antiIgA antibody ) . History anaphylaxis severe systemic response plasmaderived alpha1proteinase inhibitor preparation blood product ( ) , polysorbates . Use chronic oral steroid study . Note : Inhaled corticosteroid administer least 4 week prior Visit 1 permissible study . Use chronic , high dose ibuprofen therapy within 3 week screen anytime study . Chronic maintenance therapy systemic antibiotic within 3 week screen last dose investigational product . Use leukotriene synthesis inhibitor ( zileuton ) leukotriene receptor antagonist ( montelukast , zafirlukast ) within 3 week screen anytime study . Use roflumilast within 3 week screen time study . Initiation new chronic medication dosage change chronic medication treatment cystic fibrosis ( example : Kalydeco™ [ ivacaftor ] ) within 3 week screen ( Visit 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Alpha1-proteinase inhibitor</keyword>
	<keyword>Alpha1-antitrypsin</keyword>
</DOC>